Shukra Pharmaceuticals (524632) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
13 Nov, 2025Executive summary
Board approved unaudited financial results for the quarter and half year ended September 30, 2025, and reviewed business operations.
Statutory auditors provided an unqualified review opinion on the results.
Financial highlights
Revenue from operations for Q2 FY26 was ₹587.74 lakhs, up from ₹555.52 lakhs in Q2 FY25.
Net profit for Q2 FY26 stood at ₹237.81 lakhs, compared to ₹53.89 lakhs in Q2 FY25.
Total income for H1 FY26 was ₹1,409.08 lakhs, with net profit at ₹340.77 lakhs.
Earnings per share (EPS) for Q2 FY26 was ₹0.05, up from ₹0.02 in Q2 FY25.
Key financial ratios and metrics
Gross margin improved due to higher revenue and controlled expenses.
Equity share capital remained at ₹4,378.79 lakhs.
Other equity increased to ₹2,201.78 lakhs as of September 30, 2025.
Latest events from Shukra Pharmaceuticals
- Strong revenue and profit growth in Q1 FY27, with robust performance in the pharmaceutical segment.524632
Q1 26/27 - Revenue and net profit surged year-over-year, with robust equity and no debt defaults.524632Q4 25/26
- Q3 FY26 revenue and profit surged, with strong audit review and MD re-appointment.524632Q3 25/26
- Q1 FY26 saw strong revenue and profit growth with clean auditor review.524632Q1 25/26
- Q2 FY2024-25 revenue grew, but net profit and EPS fell; cash reserves increased.524632Q2 24/25
- Q1 FY25 saw a significant drop in revenue and profit, but auditors raised no concerns.524632Q1 24/25
- FY25 revenue and profit declined sharply, but financial position and compliance remain strong.524632Q4 24/25
- Quarterly profit and revenue surged, with strengthened audit oversight.524632Q3 24/25